Leonard I.
58
Coauthors
4
Documentos
Volumen de publicaciones por año
Cargando gráfico
Año de publicación | Num. Publicaciones |
---|---|
2004 | 1 |
2008 | 1 |
2009 | 1 |
2010 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
Área de conocimiento | Num. Publicaciones |
---|---|
Cáncer | 7 |
Publicaciones por áreas temáticas
Cargando gráfico
Área temática | Num. Publicaciones |
---|---|
Enfermedades | 4 |
Farmacología y terapéutica | 4 |
Principales fuentes de datos
Origen | Num. Publicaciones |
---|---|
Scopus | 4 |
Google Scholar | 0 |
RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
Coautor | Num. Publicaciones |
---|---|
Tania Crombet | 4 |
Carmen Elena Viada | 3 |
Lage Davila A. | 3 |
Bárbara Wilkinson | 2 |
Mazorra Z. | 2 |
González G. | 2 |
Neninger Vinageras E. | 2 |
Torres O. | 2 |
Fleites G. | 1 |
González M.J. | 1 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine
ArticleAbstract: Purpose: Epidermal growth factor (EGF) might be a suitable immunotherapeutic target in non-small-celPalabras claves:Autores:Carmen Elena Viada, De La Torre A.V., García Verdecia B., González G., Lage Davila A., Leonard I., Martínez R., Mazorra Z., Neninger Vinageras E., Tania CrombetFuentes:scopusCombining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer
ArticleAbstract: An epidermal growth factor (EGF) vaccine was given before and after standard first line chemotherapyPalabras claves:cancer vaccine, EGF, NSCLCAutores:Bárbara Wilkinson, Carmen Elena Viada, Fleites G., González G., González M.J., Lage Davila A., Leonard I., Mazorra Z., Neninger Vinageras E., Pereda S., Tania Crombet, Verdecia B.G.Fuentes:scopusUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
ArticleAbstract: Purpose: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor rPalabras claves:Autores:Alvarez D., Cruz T., Del Castillo R., Fernández E., Figueredo R., Iznaga-Escobar N., Koropatnick J., Lage Davila A., Leonard I., Mon R., Osorio M., Pérez R., Ramos M., Renginfo E., Roca C., Tania Crombet, Torres O.Fuentes:scopusNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
ArticleAbstract: The prognosis of patients with advanced head and neck cancer remain dismal. For this tumor type, elePalabras claves:Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, nimotuzumab, Squamous cell carcinoma of the head and neck, Targeted therapyAutores:Alert J., Bahi R.D.C., Bárbara Wilkinson, Bilbao M.A., Carmen Elena Viada, De Armas E.L., Frómeta M., Galainena J.J., Gracias E., Iznaga N., Leonard I., Luaces P.L.o., Muchuli C.R., Mulén B., Mullens V., Pérez K., Pineda I., Rivero T.C., Rodríguez E., Rodríguez M.O., Tania Crombet, Torres O., Vinageras E.N.Fuentes:scopus